MV Chandrakanth, Academic Head and Medical Oncologist at Narayana Health, shared on X:
“Ivonescimab:PFS win, OS miss – FDA says no!
HARMONi Phase III, FDA Complete Response Letter (CRL).
- Population: EGFR-mutated advanced nonsquamous NSCLC after 3rd-generation EGFR TKI.
- Design: Ivonescimab + platinum chemotherapy vs placebo + chemotherapy.
- PFS: Statistically significant improvement.
- OS: Not statistically significant Post-hoc HR 0.76 – favorable trend, no proven OS benefit.
- FDA verdict: Benefit-risk evidence insufficient for approval as submitted.
- Regulatory status: In the USA Not FDA-approved, in China-Initially approved May 2024.
What’s next? HARMONi-3, HARMONi-7 and broader clinical development continue.
Take-Home: PFS success ≠ OS success ≠ FDA approval.
Reference: Summit Therapeutics, November 15, 2026, HARMONi Phase III, FDA CRL announcement.”
You can also read:
